Immunotherapy in cancer. Current prospects, challenges and new horizons.
under-Recent under-standing standing of the mechanisms that control immune system homeostasis and orchestrate antitumor responses has prompted the development of novel immunotherapeutic modalities. These include antibodies that target immune checkpoints such as PD-1/PD-L1 and CTLA-4, agonistic antib...
| Publicado: |
2018
|
|---|---|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00257680_v78_n5_p336_DalottoMoreno http://hdl.handle.net/20.500.12110/paper_00257680_v78_n5_p336_DalottoMoreno |
| Aporte de: |
| id |
paper:paper_00257680_v78_n5_p336_DalottoMoreno |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_00257680_v78_n5_p336_DalottoMoreno2023-06-08T14:53:41Z Immunotherapy in cancer. Current prospects, challenges and new horizons. Biomarkers Cancer Chimeric antigen receptors Co-stimulation Immunological checkpoints Immunotherapy biological marker cytotoxic T lymphocyte antigen 4 antibody OX40 ligand programmed death 1 ligand 1 tumor necrosis factor receptor superfamily member 9 adoptive transfer antineoplastic activity Article cancer immunotherapy DNA modification human prediction T lymphocyte under-Recent under-standing standing of the mechanisms that control immune system homeostasis and orchestrate antitumor responses has prompted the development of novel immunotherapeutic modalities. These include antibodies that target immune checkpoints such as PD-1/PD-L1 and CTLA-4, agonistic antibodies of costimulatory molecules such as CD137 and OX-40 and the adoptive transfer of genetically-modified antitumor T cells. However, a large number of patients do not respond to these therapies and develop resistance as a result of activation of compensatory circuits. Rational combination of immunotherapeutic modalities will help overcome resistance and will increase the number of patients who will benefit from these treatments. Moreover, identification of predictive biomarkers will allow selection of patients responding to these treatments. Emerging clinical trials and pre-clinical studies have shown exciting results anticipating new horizons in the design and implementation of cancer immunotherapeutic modalities. © 2018, Instituto de Investigaciones Medicas. All rights reserved. 2018 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00257680_v78_n5_p336_DalottoMoreno http://hdl.handle.net/20.500.12110/paper_00257680_v78_n5_p336_DalottoMoreno |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Biomarkers Cancer Chimeric antigen receptors Co-stimulation Immunological checkpoints Immunotherapy biological marker cytotoxic T lymphocyte antigen 4 antibody OX40 ligand programmed death 1 ligand 1 tumor necrosis factor receptor superfamily member 9 adoptive transfer antineoplastic activity Article cancer immunotherapy DNA modification human prediction T lymphocyte |
| spellingShingle |
Biomarkers Cancer Chimeric antigen receptors Co-stimulation Immunological checkpoints Immunotherapy biological marker cytotoxic T lymphocyte antigen 4 antibody OX40 ligand programmed death 1 ligand 1 tumor necrosis factor receptor superfamily member 9 adoptive transfer antineoplastic activity Article cancer immunotherapy DNA modification human prediction T lymphocyte Immunotherapy in cancer. Current prospects, challenges and new horizons. |
| topic_facet |
Biomarkers Cancer Chimeric antigen receptors Co-stimulation Immunological checkpoints Immunotherapy biological marker cytotoxic T lymphocyte antigen 4 antibody OX40 ligand programmed death 1 ligand 1 tumor necrosis factor receptor superfamily member 9 adoptive transfer antineoplastic activity Article cancer immunotherapy DNA modification human prediction T lymphocyte |
| description |
under-Recent under-standing standing of the mechanisms that control immune system homeostasis and orchestrate antitumor responses has prompted the development of novel immunotherapeutic modalities. These include antibodies that target immune checkpoints such as PD-1/PD-L1 and CTLA-4, agonistic antibodies of costimulatory molecules such as CD137 and OX-40 and the adoptive transfer of genetically-modified antitumor T cells. However, a large number of patients do not respond to these therapies and develop resistance as a result of activation of compensatory circuits. Rational combination of immunotherapeutic modalities will help overcome resistance and will increase the number of patients who will benefit from these treatments. Moreover, identification of predictive biomarkers will allow selection of patients responding to these treatments. Emerging clinical trials and pre-clinical studies have shown exciting results anticipating new horizons in the design and implementation of cancer immunotherapeutic modalities. © 2018, Instituto de Investigaciones Medicas. All rights reserved. |
| title |
Immunotherapy in cancer. Current prospects, challenges and new horizons. |
| title_short |
Immunotherapy in cancer. Current prospects, challenges and new horizons. |
| title_full |
Immunotherapy in cancer. Current prospects, challenges and new horizons. |
| title_fullStr |
Immunotherapy in cancer. Current prospects, challenges and new horizons. |
| title_full_unstemmed |
Immunotherapy in cancer. Current prospects, challenges and new horizons. |
| title_sort |
immunotherapy in cancer. current prospects, challenges and new horizons. |
| publishDate |
2018 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00257680_v78_n5_p336_DalottoMoreno http://hdl.handle.net/20.500.12110/paper_00257680_v78_n5_p336_DalottoMoreno |
| _version_ |
1768543883979915264 |